Search | IOVS | ARVO Journals

Showing 1 – 20 of 20

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

Dense scotomas in patients with CNV may not correlate with the observable lesion on infrared imaging

Janet S Sunness; Carol A Applegate; Michael J Elman; John T Thompson; Ray Sjaarda; David Baranano; Lisa Schocket; Edward Goldman

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3376. doi:

ARVO Annual Meeting Abstract June 2020

Performance of a novel deep learning algorithm for Automatic Retinal Fluid Quantification in Home OCT Images

David Lally; Judy E Kim; Michael J Elman; Oren Tomkins-Netzer; Yael Alon; Elad Bergman; Anat Loewenstein

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2571. doi:

ARVO Annual Meeting Abstract June 2020

Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Choroidal Neovascularization in AMD (ForeseeHome device)

Allen Ho; Michael J Elman; David Aaron Eichenbaum; George Sanborn; Jennifer Jacobs; Gidi Benyamini; Grace C Chang

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2636. doi:

ARVO Annual Meeting Abstract June 2020

Artificial intelligence algorithm may improve performance of retinal specialists in detection of retinal fluid on OCT in age-related macular degeneration: AREDS2 10-Year follow-on Study

Michael J Elman; Tiarnan D L Keenan; Traci E Clemons; Amitha Domalpally; Moshe Havilio; Gidi Benyamini; Emily Chew

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):5275. doi:

ARVO Annual Meeting Abstract July 2019

Ranibizumab as the PrimaryTreament for Proliferative Diabetic Retinopathy in a "Real Life" Private Retina Office Setting

Itay Kazaz; Michael J Elman

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6544. doi:

ARVO Annual Meeting Abstract July 2019

Comparison Between Retinal Images Captured by a Self-Operated, Home-based Optical Coherence Tomography (OCT) System and Commercial OCT Systems

Oren Tomkins-Netzer; Michael J Elman

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1898. doi:

ARVO Annual Meeting Abstract July 2018

Clinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular DegenerationClinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular Degeneration

Michael J Elman; David M Brown; Peter K Kaiser; Jason S Slakter

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4950. doi:

ARVO Annual Meeting Abstract June 2017

Prophylactic Ranibizumab for Exudative age-related macular degeneration (AMD) in Vulnerable Eyes with Non-Exudative AMD Trial (PREVENT): A prospective controlled clinical trial

Maziar Lalezary; Steven G. Lin; Clement K Chan; Bansal S. Alok; Rahul N Khurana; Mark Wieland; Louis K Chang; James Palmer; Prema Abraham; Michael J Elman; Brandon J Lujan; Glenn Yiu

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):410. doi:

ARVO Annual Meeting Abstract September 2016

A Proof of Concept Study of Intravitreal (IVT) LFG316 In Patients with Neovascular Age Realted Macular Degeneration (nAMD)

Ron P Gallemore; Michael J Elman; Mark Milton; Parisa Zamiri; Cynthia L Grosskreutz

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4986. doi:

ARVO Annual Meeting Abstract June 2015

Long-term improvements in vision and diabetic retinopathy achieved and maintained with PRN ranibizumab therapy in the RIDE and RISE trials

Michael J Elman; Jiameng Zhang; Ivaylo Stoilov

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3145. doi:

ARVO Annual Meeting Abstract June 2015

A Phase 1 Safety Study of an Orally Available Tyrosine Kinase Inhibitor X-82 in Previously Treated Wet AMD Patients

Philip J Rosenfeld; Jason S Slakter; David S Boyer; David M Brown; Nauman A Chaudhry; Michael J Elman; Sunil S Patel; Denis O’Shaughnessy

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4804. doi:

ARVO Annual Meeting Abstract June 2015

Final Results from a Phase 2 Study of Squalamine Lactate Ophthalmic Solution 0.2% (OHR-102) in the Treatment of Neovascular Age-related Macular Degeneration (AMD)

Jason S Slakter; Thomas A Ciulla; Michael J Elman; Lawrence J Singerman; Glenn Stoller; Peter K Kaiser; Irach B Taraporewala; Sam Backenroth

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4805. doi:

ARVO Annual Meeting Abstract April 2014

The AREDS2-HOME study: Characteristics of Early CNV

Barbara A Blodi; Amitha Domalpally; Ronald P Danis; Traci E Clemons; Michael J Elman; Emily Y Chew; AREDS2-Home Study Research Group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4975. doi:

ARVO Annual Meeting Abstract June 2013

Rationale for Treating Wet AMD in Human Using an Oral Pill Consisting of a VEGFR/PDGFR Inhibitor X-82

Chris Liang; David Brown; Nauman Chaudhry; Michael Elman; Jeffrey Heier

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3272. doi:

ARVO Annual Meeting Abstract June 2013

Development of Choroidal Neovascularization in the Second Eye of Neovascular AMD Patients Treated with Anti-VEGF Drugs

Jonah Abraham; Michael Elman

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4156. doi:

ARVO Annual Meeting Abstract June 2013

ForeseeHome in AREDS2-Home Monitoring of AMD patients: Study Design, Enrollment, Baseline Characteristics and Initial Device Usage

Michael Elman; Susan Bressler; Traci Clemons; Emily Chew; AREDS2 ForeSee Home Monitoring Research Group

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):6273. doi:

ARVO Annual Meeting Abstract March 2012

A Novel Eye Drop Formulation of Squalamine For Exudative AMD: Evaluation Of Ocular Distribution And Ocular Safety In Rabbits

Irach B. Taraporewala; Michael J. Elman; Shalom Z. Hirschman; Samuel I. Backenroth

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):457. doi:

ARVO Annual Meeting Abstract April 2010

Pooled Analysis of the Relationship of OCT-Measured Central Retinal Thickness With Visual Acuity and Level of Diabetic Retinopathy in DRCR Network Studies

M. J. Elman; Diabetic Retinopathy Clinical Research Network

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):4665. doi:

ARVO Annual Meeting Abstract May 2008

Endophthalmitis Following Anti-VEGF Injections in a Retinal Practice Setting

M. Elman; A. Elman; A. Glasser; D. Braver

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):976. doi:

ARVO Annual Meeting Abstract May 2004

Verteporfin In Treatment of Diabetic Macular Edema (VIDME) – 3–Month Results of a Phase I/II Placebo–Controlled Clinical Trial

M.J. Elman; R.Z. Raden; A. Carrigan; M. Sloan; G. Williams; VIDME Study Group

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3184. doi:

NARROW

Content Type

Journal

Article Type

Specify Date Range

Dense scotomas in patients with CNV may not correlate with the observable lesion on infrared imaging

Performance of a novel deep learning algorithm for Automatic Retinal Fluid Quantification in Home OCT Images

Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Choroidal Neovascularization in AMD (ForeseeHome device)

Artificial intelligence algorithm may improve performance of retinal specialists in detection of retinal fluid on OCT in age-related macular degeneration: AREDS2 10-Year follow-on Study

Ranibizumab as the PrimaryTreament for Proliferative Diabetic Retinopathy in a "Real Life" Private Retina Office Setting

Comparison Between Retinal Images Captured by a Self-Operated, Home-based Optical Coherence Tomography (OCT) System and Commercial OCT Systems

Prophylactic Ranibizumab for Exudative age-related macular degeneration (AMD) in Vulnerable Eyes with Non-Exudative AMD Trial (PREVENT): A prospective controlled clinical trial

A Proof of Concept Study of Intravitreal (IVT) LFG316 In Patients with Neovascular Age Realted Macular Degeneration (nAMD)

Long-term improvements in vision and diabetic retinopathy achieved and maintained with PRN ranibizumab therapy in the RIDE and RISE trials

A Phase 1 Safety Study of an Orally Available Tyrosine Kinase Inhibitor X-82 in Previously Treated Wet AMD Patients

Final Results from a Phase 2 Study of Squalamine Lactate Ophthalmic Solution 0.2% (OHR-102) in the Treatment of Neovascular Age-related Macular Degeneration (AMD)

The AREDS2-HOME study: Characteristics of Early CNV

Rationale for Treating Wet AMD in Human Using an Oral Pill Consisting of a VEGFR/PDGFR Inhibitor X-82

Development of Choroidal Neovascularization in the Second Eye of Neovascular AMD Patients Treated with Anti-VEGF Drugs

ForeseeHome in AREDS2-Home Monitoring of AMD patients: Study Design, Enrollment, Baseline Characteristics and Initial Device Usage

A Novel Eye Drop Formulation of Squalamine For Exudative AMD: Evaluation Of Ocular Distribution And Ocular Safety In Rabbits

Pooled Analysis of the Relationship of OCT-Measured Central Retinal Thickness With Visual Acuity and Level of Diabetic Retinopathy in DRCR Network Studies

Endophthalmitis Following Anti-VEGF Injections in a Retinal Practice Setting

Verteporfin In Treatment of Diabetic Macular Edema (VIDME) – 3–Month Results of a Phase I/II Placebo–Controlled Clinical Trial

To View More...

You must be signed into an individual account to use this feature.